TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02085577
Drug: Morphine Sulphate 1 mg/ml
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
Study: NCT02085577
Drug: Ondansetron 2 mg/ml
Normalized name: ondansetron 2 MG/ML
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
Study: NCT02085577
Drug: Morphine Sulphate 1 mg/ml
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
Study: NCT02308280
Drug: Bortezomib following nonmyeloablative allogeneic transplant
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
Study: NCT03103399
Drug: Nebicapone
Normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
Study: NCT01821963
Drug: Pegylated Interferon Alfa 2a
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose: 180 mcg subcutaneously once weekly.
Study: NCT01821963
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose: 1,000 mg by mouth daily.
Study: NCT01821963
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose: 750 mg by mouth 3 times a day.
Study: NCT00252863
Drug: Budesonide Turbuhaler 200 µg
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00252863
Drug: Fluticasone Discus 250 µg
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00252863
Drug: Formoterol Turbuhaler 4.5 µg
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00252863
Drug: Terbutaline Turbuhaler 0.5 mg
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00252863
Drug: Salbutamol pressurized metered dose inhaler (pMDI) 100 µg
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00252863
Drug: Salmeterol Discus 50 µg
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00252863
Drug: Budesonide/Formoterol Turbuhaler 160/4.5 µg
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00252863
Drug: Fluticasone/Salmeterol Discus 250/50 µg
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00252863
Drug: Fluticasone/Salmeterol Discus 500/50 µg
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00252863
Drug: Singulair 10 mg
Normalized name: Singulair 10 MG Oral Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03952130
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT03952130
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT03952130
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT03251690
Drug: Tenofovir/Emtricitabine/Rilpivirine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
Study: NCT03251690
Drug: Tenofovir/Emtricitabine/Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: as a active comparator
Study: NCT02928419
Drug: Eltrombopag/Revolade
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted.
Study: NCT02928419
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
Study: NCT03933501
Drug: amoxicillin and metronidazole
Normalized name: omeprazole, amoxicillin and metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
Study: NCT02396147
Drug: TAK-385 T4 Formulation C
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAK-385 T4 Formulation C tablets
Study: NCT01789879
Drug: Levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
Study: NCT01789879
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
Study: NCT01789879
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
Study: NCT00004934
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004934
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004934
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00147771
Drug: Imiquimod 5% cream
Normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
Study: NCT04352660
Drug: Mitomycin-C injection
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC delivered by preoperative subconjunctival injection
Study: NCT04352660
Drug: Mitomycin-C sponge
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Study: NCT02832271
Drug: SUNPHENON EGCg
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUNPHENON EGCg Oral, 400mg, twice per day
Study: NCT04889677
Drug: Danicopan
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01439009
Drug: Placebo of tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once-daily oral administration of one placebo tablet in the morning
Study: NCT02357277
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: inhaled glucocorticoid budesonide as dry powder inhaler
Study: NCT00003995
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00964691
Drug: Sulphadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
Study: NCT00964691
Drug: Chloroquine prophylaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
Study: NCT01688648
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
Study: NCT01688648
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
Study: NCT02325882
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine mixed fentanyl based intravenous PCA
Study: NCT00228449
Drug: peginesatide
Normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03109951
Drug: Colonoscopy preparation using polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
Study: NCT02652819
Drug: FG-4592
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02859701
Drug: AK002
Normalized name: MONOCLONAL ANTIBODY AK002
DrugBank: Lirentelimab (DB16728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV AK002
Study: NCT02163330
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02163330
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01718314
Drug: Sublingual Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01718314
Drug: Lidocaine pump spray
Normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00292123
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02007239
Drug: tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
Study: NCT00719810
Drug: delafloxacin
Normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg intravenous every 12 hours
Study: NCT00719810
Drug: delafloxacin
Normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 450 mg intravenous every 12 hours
Study: NCT00430781
Drug: pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00430781
Drug: lapatinib (GW572016)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00882713
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
Study: NCT00124540
Drug: misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03976401
Drug: EFX
Normalized name: XENADRIN EFX EPHEDRINE FREE
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT00262106
Drug: PRO 2000/5
DrugBank: PRO 2000 (DB05385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: NCT00149214
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
Study: NCT00149214
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
Study: NCT04284644
Drug: Induction using propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.
Study: NCT04284644
Drug: Induction using sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.
Study: NCT04284644
Drug: Induction using propofol and sevoflurane
Normalized name: Sevoflurane
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
Study: NCT03227926
Drug: Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
Study: NCT00793923
Drug: ranibizumab and dexamethasone
Normalized name: Ranibizumab
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
Study: NCT00793923
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of 0.5 mg ranibizumab
Study: NCT00283712
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
Study: NCT02446782
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
Study: NCT03385668
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
Study: NCT00234949
Drug: cefdinir
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00234949
Drug: cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02282761
Drug: ITI-007
Normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003565
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01382069
Drug: Dimethandrolone Undecanoate
Normalized name: Dimethandrolone Undecanoate
DrugBank: Dimethandrolone Undecanoate (DB16141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
Study: NCT01277146
Drug: OMP-59R5
Normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00543647
Drug: Fenofibrate 160 mg tablet
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00184990
Drug: Aminoguanidine
Normalized name: Aminoguanidine
DrugBank: Pimagedine (DB05383)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01673061
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See associated Arm Description
Study: NCT00844883
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sorafenib: given 400 mg twice per day for as long as it is beneficial
Study: NCT02498652
Drug: allopurinol 300 mg
Normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
Study: NCT01103050
Drug: QAV680 + Cetirizine Placebo
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01103050
Drug: QAV680 + Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01103050
Drug: Cetirizine + QAV680 Placebo
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01103050
Drug: QAV680 Placebo + Cetirizine Placebo
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00816218
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pioglitazone, 45 mg daily
Study: NCT03749642
Drug: trazodone/gabapentin 2.5/25 mg
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
Study: NCT03749642
Drug: trazodone/gabapentin 5/50 mg
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
Study: NCT03749642
Drug: trazodone/gabapentin 10/100
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
Study: NCT03749642
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The total daily doses administered will be:~* 600 mg from day 0 to day 6 (±1)~* 900 mg from day 7 (±1) to day 13 (±1)~* 1200 mg from day 14 (±1) to day 20 (±1)~* 1800 mg from day 21 (±1) to day 56 (±2)
Study: NCT02049528
Drug: CC-122
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-122
Study: NCT00005860
Drug: floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005860
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00923091
Drug: olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo
Normalized name: amlodipine / hydrochlorothiazide / olmesartan medoxomil Pill
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
Study: NCT00923091
Drug: olmesartan medoxomil + amlodipine + hydroclororthiazide
Normalized name: amlodipine / hydrochlorothiazide / olmesartan medoxomil Pill
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
Study: NCT00923091
Drug: olmesartan medoxomil + amlodipine + hydroclororthiazide
Normalized name: amlodipine / hydrochlorothiazide / olmesartan medoxomil Pill
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
Study: NCT00923091
Drug: olmesartan medoxomil + amlodipine + hydroclororthiazide
Normalized name: amlodipine / hydrochlorothiazide / olmesartan medoxomil Pill
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
Study: NCT00923091
Drug: olmesartan medoxomil + amlodipine
Normalized name: amlodipine / olmesartan medoxomil Pill
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
Study: NCT00923091
Drug: olmesartan medoxomil + amlodipine
Normalized name: amlodipine / olmesartan medoxomil Pill
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
Study: NCT00923091
Drug: olmesartan medoxomil + amlodipine
Normalized name: amlodipine / olmesartan medoxomil Pill
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
Study: NCT02140320
Drug: RV1729 14 day repeat dose
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses
Study: NCT02140320
Drug: RV1729 28 day repeat dose
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses